Cancers, Vol. 12, Pages 1867: Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

Cancers, Vol. 12, Pages 1867: Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study Cancers doi: 10.3390/cancers12071867 Authors: Shigeo Shimose Hideki Iwamoto Takashi Niizeki Tomotake Shirono Yu Noda Naoki Kamachi Shusuke Okamura Masahito Nakano Hideya Suga Ryoko Kuromatsu Taizo Yamaguchi Takumi Kawaguchi Masatoshi Tanaka Kazunori Noguchi Hironori Koga Takuji Torimura We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors associated with DLSAE were advanced age, albumin-bilirubin (ALBI) grade 2, fatigue grade ≥ 3, and appetite loss ≥ 2. The overall survival (OS) in the group that did not require DLSAE was significantly longer compared to the group that did require DLSAE (median survival time (MST): not reached vs. 12.8 months, p < 0.001). Moreover, advanced age was the most important variable for DLSAE in a decision tree analysis. Hypertension and hand-foot-skin-reaction (HFSR) were also significantly associated with longer survival, and the occurrence of hypertension was the earliest predictor for improved prognosis, while appetite loss and development of grade &...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research